1. Articles in category: Cells and Stem Cells

    1-24 of 217 1 2 3 4 5 6 7 8 9 »
    1. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    2. Management of Neuroblastoma: ICMR Consensus Document.

      Management of Neuroblastoma: ICMR Consensus Document.

      Indian J Pediatr. 2017 Apr 03;:

      Authors: Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S

      Abstract Neuroblastoma (NBL) is the most common extra-cranial solid tumor in childhood. High-risk NBL is considered challenging and has one of the least favourable outcomes amongst pediatric cancers.

      Read Full Article
      Mentions: Staging Relapse MYCN
    3. Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Int J Clin Oncol. 2017 Mar 31;:

      Authors: Tomioka A, Maru M, Kashimada K, Sakakibara H

      Abstract BACKGROUND: Female childhood cancer survivors who develop gonadal dysfunction require female hormone replacement therapy (HRT) from puberty until menopause. However, the support provided in such cases has not been studied.

      Read Full Article
    4. Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Mol Ther Oncolytics. 2017 Mar 17;4:67-76

      Authors: Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS

      Read Full Article
    5. HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      Am J Cancer Res. 2017;7(2):334-345

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Read Full Article
    6. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    7. A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).

      A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).

      Sci Rep. 2017 Dec;7(1):41

      Authors: Yang XH, Tang F, Shin J, Cunningham JM

      Abstract c-Myc dysregulation is hypothesized to account for the 'stemness' - self-renewal and pluripotency - shared between embryonic stem cells (ESCs) and adult aggressive tumours.

      Read Full Article
    8. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.

      Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.

      BMC Cancer. 2017 Feb 24;17(1):156

      Authors: Bayat Mokhtari R, Baluch N, Ka Hon Tsui M, Kumar S, S Homayouni T, Aitken K, Das B, Baruchel S, Yeger H

      Abstract BACKGROUND: Neuroblastoma (NB), a tumor of the primitive neural crest, despite aggressive treatment portends a poor long-term survival for patients with advanced high stage NB. New treatment strategies are required.

      Read Full Article
      Mentions: Treatment
    9. Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Oncotarget. 2017 Feb 08;:

      Authors: Singhal SS, Singhal S, Singhal P, Singhal J, Horne D, Awasthi S

      Abstract Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes.

      Read Full Article
      Mentions: Treatment MYCN
    10. Two investigational antitumor agents work better together against MPNST and neuroblastoma

      Two investigational antitumor agents work better together against MPNST and neuroblastoma

      Two investigational agents, Aurora A kinase inhibitor (alisertib) and HSV1716, a virus derived from HSV-1 and attenuated by the deletion of RL1, have shown some antitumor efficacy in early clinical trials as monotherapies. A new study published last week in Oncotarget, however, demonstrates that the combined usage of the agents results in significantly increased antitumor efficacy in models of malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma.

      Read Full Article
    11. Clinical characteristics of infant neuroblastoma and a summary of treatment outcome.

      Clinical characteristics of infant neuroblastoma and a summary of treatment outcome.

      Oncol Lett. 2016 Dec;12(6):5356-5362

      Authors: Zhang Y, Huang D, Zhang W, Tang S, Han T, Zhu X, Liu A, Zhi T

      Abstract Neuroblastoma (NB) is the most common malignant solid tumor in the peripheral nervous system in infants and young children, with a high degree of malignancy. The clinical characteristics and prognosis of NB in infants are unique.

      Read Full Article
      Mentions: Treatment NSE
    12. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue.

      Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue.

      Bone Marrow Transplant. 2017 Jan 09;:

      Authors: Utriainen P, Vatanen A, Toiviainen-Salo S, Saarinen-Pihkala U, Mäkitie O, Jahnukainen K

      Read Full Article
      Mentions: Bone Marrow
    13. Incorporation of high-dose (131) I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplanta

      Incorporation of high-dose (131) I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation.

      Pediatr Blood Cancer. 2016 Dec 24;:

      Authors: Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH, Koo HH

      Read Full Article
      Mentions: Treatment MIBG GvHD
    14. Resistance of stem-like cells from neuroblastoma cell lines to commonly used anticancer drugs.

      "Neuroblastoma lines SK-N-BE and SK-N-SH had 2% and 8% cells expressing CD133 respectively, while SH-SY-5Y had no CD133 expressing cells. CD133 + cells showed significant resistance to all four drugs in the MTT assay as well as the PI/Annexin binding assay compared to CD 133 - cells. This study suggests that CD133+ cells in neuroblastoma cell lines are more resistant to conventional anti-cancer drugs compared to CD133- cells. Targeting these stem-like cell populations could lead to development of more effective treatment for neuroblastoma."

      Read Full Article
      Mentions: Relapse
    15. CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.

      "Patients with neural crest-derived tumors often have poor outcomes due to frequent relapses, likely due to the continued presence of residual treatment-resistant CSCs, and therapies directed against these CSCs are likely to improve patient outcomes. CSCs share many of the same genetic and biologic features of primordial neural crest cells, and therefore a better understanding of neural crest development will likely lead to the development of effective therapies directed against these CSCs. Signaling through STAT3 has been shown to be required for neural crest development, and granulocyte colony stimulating factor (GCSF)-mediated activation of STAT3 has been shown to play ...

      Read Full Article
    16. Loss of a microRNA family, let-7, found key in neuroblastoma

      Loss of a microRNA family, let-7, found key in neuroblastoma

      "The let-7 family of microRNAs (bits of genetic code that regulate genes) is known to be involved in both stem-cell differentiation and tumor suppression. Recent research had implicated LIN28B, a protein that inhibits let-7 maturation, in neuroblastoma. But the new study, through work on neuroblastoma cells and analysis of patient data, found that LIN28B is only one of several cancer mechanisms that involve let-7 suppression.  "We're showing that let-7 inhibition is central to the development of this disease," Powers says. "So critical in fact that neuroblastoma uses at least three distinct ways of eliminating it."  Powers and colleagues first ...

      Read Full Article
      Mentions: MYCN Chemotherapy
    17. Induced differentiation inhibits sphere formation in neuroblastoma.

      "Here, we show that MYCN-amplified neuroblastoma cell lines form spheres more frequently than non-MYCN-amplified cell lines. We also show that sphere formation is directly sensitive to cellular differentiation status. 13-cis-retinoic acid is a clinically used differentiating agent that induces a neuronal phenotype in neuroblastoma cells. Induced differentiation nearly completely blocked sphere formation. Furthermore, sphere formation was specifically FGF-responsive and did not respond to increasing doses of EGF. Taken together, these data suggest that sphere formation is an accurate method of quantifying the stemness phenotype in neuroblastoma."

      Read Full Article
      Mentions: Treatment MYCN
    18. Programming of donor T cells using allogeneic delta-like ligand 4-positive dendritic cells to reduce GVHD in mice.

      Programming of donor T cells using allogeneic delta-like ligand 4-positive dendritic cells to reduce GVHD in mice.

      Blood. 2016 May 3;

      Authors: Mochizuki K, Meng L, Mochizuki I, Tong Q, He S, Liu Y, Purushe J, Fung H, Zaidi MR, Zhang Y, Reshef R, Blazar BR, Yagita H, Mineishi S, Zhang Y

      Read Full Article
    19. Investigation of the Effects of an Exercise Program on Physical Functions and Activities of Daily Life in Pediatric Hematopoietic Stem Cell Transplantation

      The aim of this study was to determine the effectiveness of an implemented exercise program for children throughout the hematopoietic stem cell transplantation (HSCT) process.

      Twenty-two children aged between 3 and 17, who were earlier selected for HSCT, were divided into two groups—intervention and control. Children's physical function, functional performance, and activities of daily life (ADL) were assessed before HSCT, at discharge, and 1 month later.

      Read Full Article
    20. Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.

      Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.

      Bone Marrow Transplant. 2016 Apr 25;

      Authors: Dourthe ME, Ternès N, Gajda D, Paci A, Dufour C, Benhamou E, Valteau-Couanet D

      PMID: 27111042 [PubMed - as supplied by publisher]

      Read Full Article
    21. Remission With Donor Lymphocyte Infusion in a Child With Marrow Relapse After Haploidentical Stem Cell Transplantation for Relapsed Stage 4 Neuroblastoma.

      Remission With Donor Lymphocyte Infusion in a Child With Marrow Relapse After Haploidentical Stem Cell Transplantation for Relapsed Stage 4 Neuroblastoma.

      Pediatr Blood Cancer. 2016 Apr 21;

      Authors: Liu AP, Leung RY, Cheuk KL, Lee PP, Chiang AK, Ha SY, Chan GC

      Read Full Article
    1-24 of 217 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) MYCN
  4. General Informations in the News

    1. (1 articles) Staging
  5. Treatments in the News

    1. (1 articles) MIBG
    2. (1 articles) Relapse